British Journal of Dermatology

Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis.  187:438-441. 2022

A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial*.  184:1047-1058. 2021

Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study*.  184:425-436. 2021

Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial*.  184:450-463. 2021

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of VT-1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail*.  184:270-280. 2021

New effects of caffeine on corticotropin-releasing hormone (CRH)-induced stress along the intrafollicular classical hypothalamic–pituitary–adrenal (HPA) axis (CRH-R1/2, IP3-R, ACTH, MC-R2) and the neurogenic non-HPA axis (substance P, p75^NTR and TrkA) in ex vivo human male androgenetic scalp hair follicles.  184:96-110. 2021

Treatment-resistant tinea corporis, a potential public health issue.  184:164-165. 2021

A call for antifungal stewardship.  183:798-799. 2020

A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.  182:1348-1358. 2020

Rosacea treatment: a patient-centric approach.  182:1090-1091. 2020

The clinical course of actinic keratosis correlates with underlying molecular mechanisms.  182:995-1002. 2020

Erdheim–Chester disease: expanding the spectrum of cutaneous manifestations.  182:405-409. 2020

Targeting melanocortin receptor type 1 with small peptides.  181:17-18. 2019

Natural history of lesions suspicious for basal cell carcinoma in older adults in Ikaria, Greece.  179:767-768. 2018

Image Gallery: Molluscum contagiosum-like facial lesions in a patient with a renal transplant: deep dermatophytosis due to Trichophyton rubrum.  178:e328. 2018

Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative).  178:e332-e341. 2018

Mosaicism for a SPRED1 deletion revealed in a patient with clinically suspected mosaic neurofibromatosis.  176:1077-1078. 2017

Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement.  176:979-984. 2017

More than skin-deep: is basal cell carcinoma a marker for a cancer-prone phenotype?.  176:305-306. 2017

Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative).  175:69-79. 2016

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Results from two randomized, placebo-controlled, phase III trials.  173:949-961. 2015

Topical application of delphinidin reduces psoriasiform lesions in the flaky skin mouse model by inducing epidermal differentiation and inhibiting inflammation.  172:354-364. 2015

Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME).  171:1318-1325. 2014

Methotrexate use and liver disease - A causal relationship?.  171:6-7. 2014

Ultraviolet radiation regulates cortisol activity in a waveband-dependent manner in human skin ex vivo.  168:595-601. 2013

A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis.  166:389-398. 2012

BRAF V600E mutation and the tumour suppressor IGFBP7 in atypical genital naevi.  162:677-680. 2010

Visualizing CD4 T-cell migration into inflamed skin and its inhibition by CCR4/CCR10 blockades using in vivo imaging model.  162:487-496. 2010

On the role of the corticotropin-releasing hormone signalling system in the aetiology of inflammatory skin disorders.  160:229-232. 2009

C16 laminin peptide increases angiotropic extravascular migration of human melanoma cells in a shell-less chick chorioallantoic membrane assay.  157:780-782. 2007

Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis.  156:138-142. 2007

Corticotropin-releasing hormone triggers differentiation in HaCaT keratinocytes.  152:474-480. 2005

Multiple dermatofibroma-like lesions in a human immunodeficiency virus-positive patient coinfected with visceral leishmaniasis [13].  148:185-187. 2003

A higher prevalence of onychomycosis in psoriatics compared with non- psoriatics: A multicentre study.  136:786-789. 1997

Cutaneous mycoses in children.  134:7-11. 1996

Bacillary angiomatosis with cutaneous and oral lesions in an HIV‐infected patient from the U.K..  132:113-115. 1995

An inflammatory eruption associated with recombinant human IL‐6.  130:534-536. 1994

Molluscum contagiosum and the acquired immunodeficiency syndrome: clinical and immunological details of two cases.  116:131-138. 1987

Bleomycin‐induced cutaneous toxicity in the rat: analysis of histopathology and ultrastructure compared with progressive systemic sclerosis (scleroderma.  108:679-686. 1983